PE20080149A1 - Formulacion liquida acuosa que comprende un beta bloqueador - Google Patents

Formulacion liquida acuosa que comprende un beta bloqueador

Info

Publication number
PE20080149A1
PE20080149A1 PE2007000532A PE2007000532A PE20080149A1 PE 20080149 A1 PE20080149 A1 PE 20080149A1 PE 2007000532 A PE2007000532 A PE 2007000532A PE 2007000532 A PE2007000532 A PE 2007000532A PE 20080149 A1 PE20080149 A1 PE 20080149A1
Authority
PE
Peru
Prior art keywords
formulation
aqueous liquid
liquid formulation
weight
amount
Prior art date
Application number
PE2007000532A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Gerald Beddies
Georg Schulte
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20080149A1 publication Critical patent/PE20080149A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA FORMULACION LIQUIDA ACUOSA QUE COMPRENDE: A) UN BETABLOQUEANTE EN FORMA DISUELTA TAL COMO BISOPROLOL QUE SE ENCUENTRA EN UNA CANTIDAD DE HASTA 1% EN PESO DE LA FORMULACION; B) UN ESPESANTE SOLUBLE EN AGUA TAL COMO HIDROXIPROPILCELULOSA O HIDROXIPROPILMETILCELULOSA QUE SE ENCUENTRA EN UNA CANTIDAD DE 1% A 10% EN PESO DE LA FORMULACION; C) SUSTANCIAS SABORIZANTES Y AROMATIZANTES TAL COMO AZUCAR Y AROMA DE VAINILLA; D) UN AGENTE CONSERVANTE TAL COMO BENZOATO DE SODIO EN UNA CANTIDAD DE 0,01% A 1% EN PESO DE LA FORMULACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES EN ANIMALES
PE2007000532A 2006-05-02 2007-04-27 Formulacion liquida acuosa que comprende un beta bloqueador PE20080149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006020604A DE102006020604A1 (de) 2006-05-02 2006-05-02 Flüssige Arzneimittelformulierung

Publications (1)

Publication Number Publication Date
PE20080149A1 true PE20080149A1 (es) 2008-04-06

Family

ID=38180418

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000532A PE20080149A1 (es) 2006-05-02 2007-04-27 Formulacion liquida acuosa que comprende un beta bloqueador

Country Status (23)

Country Link
US (1) US20090264535A1 (es)
EP (1) EP2015728A2 (es)
JP (1) JP2009535368A (es)
KR (1) KR20090014183A (es)
CN (1) CN101431981A (es)
AR (1) AR060730A1 (es)
AU (1) AU2007245911A1 (es)
BR (1) BRPI0711140A2 (es)
CA (1) CA2650786A1 (es)
CO (1) CO6180495A2 (es)
CR (1) CR10407A (es)
DE (1) DE102006020604A1 (es)
EC (1) ECSP088850A (es)
GT (1) GT200800235A (es)
IL (1) IL195034A0 (es)
MX (1) MX2008013873A (es)
PE (1) PE20080149A1 (es)
RU (1) RU2008147216A (es)
SV (1) SV2008003080A (es)
TW (1) TW200808373A (es)
UY (1) UY30315A1 (es)
WO (1) WO2007124869A2 (es)
ZA (1) ZA200809269B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507918A (ja) * 2007-12-27 2011-03-10 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング β−遮断薬を使用する心疾患の処置
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
KR20150120008A (ko) * 2014-04-16 2015-10-27 씨제이헬스케어 주식회사 비소프롤롤 및 로수바스타틴을 포함하는 경구용 약제학적 복합제제
EA033298B1 (ru) 2015-03-03 2019-09-30 Саниона А/С Комбинированная лекарственная форма тезофензина и метопролола
GB202207690D0 (en) * 2022-05-25 2022-07-06 Zentiva Ks Liquid pharmaceutical formulation of bisoprolol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4600708A (en) * 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6335335B2 (en) * 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
RU2008147216A (ru) 2010-06-10
BRPI0711140A2 (pt) 2011-08-23
CO6180495A2 (es) 2010-07-19
CN101431981A (zh) 2009-05-13
EP2015728A2 (de) 2009-01-21
AU2007245911A1 (en) 2007-11-08
WO2007124869A3 (de) 2008-04-17
TW200808373A (en) 2008-02-16
KR20090014183A (ko) 2009-02-06
MX2008013873A (es) 2008-11-14
UY30315A1 (es) 2007-11-30
CR10407A (es) 2009-03-30
CA2650786A1 (en) 2007-11-08
SV2008003080A (es) 2009-11-26
GT200800235A (es) 2010-04-28
JP2009535368A (ja) 2009-10-01
AR060730A1 (es) 2008-07-10
ZA200809269B (en) 2009-12-30
IL195034A0 (en) 2009-08-03
ECSP088850A (es) 2008-12-30
WO2007124869A2 (de) 2007-11-08
US20090264535A1 (en) 2009-10-22
DE102006020604A1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
PE20161408A1 (es) Composiciones de insulina de rapida accion
UY32765A (es) Preparaciones insulinicas de accion lenta
AR095114A1 (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MX2016006641A (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
AR069792A1 (es) Composicion agroquimica y metodo para preparar la misma
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
PE20171334A1 (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia
MEP14508A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
ES2720954T3 (es) Formulaciones estabilizadas de estatina
UY31780A (es) Fenoxibenzamidas sustituidas
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
BRPI0514109A (pt) sistema de administração na forma de uma mistura dinámica, composição para perfumar, artigo para consumidor, artigo perfumado, e, usos de um sistema de administração e de um derivado de hidrazina
PE20061245A1 (es) Composiciones para la transmision transmucosa oral de la metformina
EA201071235A1 (ru) Жидкая композиция для деферипрона с приятным вкусом
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos

Legal Events

Date Code Title Description
FC Refusal